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Abstract
Paediatric obesity has significant physic, social and psychological implications. Childhood 
obesity is usually associated in adulthood with increased risk of type 2 diabetes, meta-
bolic syndrome and cardiovascular diseases. Aggregation of cardiometabolic risk factors 
is already observed at young ages, with a nonlinear association with enhancement of 
adiposity. Adiponectin is an adipokine that inhibits inflammation, oxidative stress and 
metabolic syndrome components, namely dyslipidaemia, high blood pressure and insu-
lin resistance. Obesity has been associated with hypoadiponectinaemia in both adult and 
paediatric patients, which may contribute to co‐morbidities observed in these patients. 
Interventional studies that aim to tackle obesity reported controversial results. Although 
the general positive effect on weight loss, inflammatory and cardiometabolic markers has 
been studied, the impact of these interventional studies on adiponectin remains unclear. 
Some studies reported that the improvement in adiponectin might only occur in paediat-
ric obese patients with great weight loss or intensive physical exercise; the magnitude of 
the changes in body composition appears to be of particular importance. A revision about 
the knowledge on the relation between adiponectin, inflammation and cardiometabolic 
risk factors in paediatric patients is performed; the impact of interventional studies on 
adiponectin levels and markers of cardiometabolic risk is also addressed.
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1. Introduction
The worldwide increase in obesity at paediatric ages has been accompanied by the appear-
ance of diseases that were considered exclusive of adults, namely type 2 diabetes (T2D), 
dyslipidaemia and hypertension. These pathologies are commonly associated with central 
obesity, and this association is related with increased cardiometabolic risk [1, 2].
Obesity is closely associated with hypoadiponectinaemia, and low levels of circulating adi-
ponectin are a potential predictor of some obesity‐related co‐morbidities. Therefore, adipo-
nectin has been studied as a possible link between these conditions. Furthermore, growing 
evidence supports a relationship between obesity in childhood and low levels of adiponectin, 
and increased cardiometabolic risk factors in adulthood [3, 4].
2. Adiponectin and its isoforms
Adiponectin is important as a mediator of inflammatory factors and as an anti‐athero-
genic, anti‐dyslipidaemic and insulin sensitiser factor. Adiponectin has particular char-
acteristics,  different from most of the other mediators: each one of its three circulating 
isoforms (high‐ (HMW), medium‐ (MMW) and low‐molecular weight (LMW)) appears 
to be linked with different,  sometimes opposite, actions in the organism. High‐molecular 
weight (HMW) isoform has been considered a better metabolic marker than total adipo-
nectin [5, 6].
Total and HMW adiponectin concentration were reported to be lower in obese (OB) chil-
dren and adolescents, when compared to lean controls (CT) [6, 7]. Besides, the relative 
percentages of the isoforms are, usually, altered: HMW% adiponectin decreases, while 
low‐molecular weight (LMW)% adiponectin increases. In children, HMW adiponectin 
multimer is usually linked to an improvement in insulin resistance (IR) and lipid pro-
file [6], and it has been negatively associated with cardiometabolic complications [8]. The 
negative associations of HMW adiponectin with IR and adiposity appear to be present 
even in pre‐pubertal (PP) individuals [9, 10]. Zimmet et al. reported that in PP children, 
HMW adiponectin was negatively associated with body mass index (BMI) z‐score, IR, tri-
glycerides (TG), leptin and soluble intracellular adhesion molecule (sICAM); however, 
after adjustment for age and sex, only BMI z‐score and TG maintained their negative asso-
ciation with HMW adiponectin [11]. These authors did not detect correlations between 
HMW adiponectin and proinflammatory mediators, such as resistin, interleukin (IL)‐8 and 
IL‐18 [11]. This lack of correlation with inflammatory mediators suggests that the levels of 
adiponectin multimers might be more linked to changes in glucose and lipid metabolisms 
at young ages.
Figure 1 resumes the reported associations between total, HMW and LMW adiponectin with 
inflammatory mediators, hormones and other factors [12–31].
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3. Adiponectin and the risk of developing co‐morbidities
Some contradiction exists in literature regarding adiponectin levels in young OB patients. 
Total adiponectin levels are generally accepted to be lower in OB children and adolescents 
Figure 1. Studies reporting associations between inflammatory markers and total, high‐molecular weight (HMW) 
and low‐molecular weight (LMW) adiponectin. Underlined are the inflammatory factors that appear in both columns 
(ambiguous results). °, pre‐pubertal; *, post‐pubertal; Ac, acid; CRP, C‐reactive protein; FABP, fat acid‐binding protein; 
FGF, fibroblast growth factor; IL, interleukin; IFN, interferon; MCP, monocyte chemoattractant protein; NEFA, non‐
esterified fatty acid; RBP, retinol‐binding protein; T4, thyroxine; TNF, tumour necrosis factor.
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when compared with CT and overweight (OW) subjects [25, 32]. However, contradictory data 
have also been reported [12, 33].
Cardiometabolic risk factors, such as dyslipidaemia, hyperglycaemia, hypertension, central 
obesity and IR, tend to cluster and are associated with increased risk for cardiovascular 
 diseases (CVDs) [1, 2]. These risk factors are already altered in early ages in OB individu-
als, and changes in adiponectin levels may underlie such risk. Indeed, an association of 
adiponectin with metabolic risk factors [1, 34] has been reported, leading to the proposal of 
adiponectin as a marker of cardiometabolic risk [24, 35], and as a potential predictor of obe-
sity‐related co‐morbidities [36, 37]. An association between adiponectin levels in childhood 
and the probability of developing co‐morbidities in the future has been also raised [21]. In 
agreement, a study by Morrison et al. showed that lower levels of adiponectin in 16‐year‐
old females were related with the development of cardiometabolic risk features at the age 
of 23 years [38]. Another study also showed adiponectin as a predictor of cardiometabolic 
risk, in OW children, even when adjusted for age, gender, Tanner stage, BMI, visceral fat 
and IR [34].
In T2D OB adolescents, adiponectin levels were found to be lower than in normal individu-
als, and even lower than in OB individuals without T2D. In this population, IR appeared as 
a main determinant of adiponectin concentrations, more than BMI itself [2]. There are, how-
ever, controversial data about the changes in adiponectin, in OB adolescents with and without 
T2D [23].
In obesity, it is important to consider body fat distribution, besides weight excess. Indeed, 
increased abdominal obesity has been associated with lower levels of adiponectin [1, 25, 
39, 40] and adiponectin was negatively associated with visceral‐to‐subcutaneous fat ratio [41]. 
The association between hypoadiponectinaemia and increased visceral adipose tissue (VAT) 
seems to appear early in life [33].
Younger age of adiposity rebound (AAR) associates with increased adiposity later in life 
[42, 43]. Nevertheless, no association was found between AAR and adiponectin in 10‐year‐old 
children, whereas an association was found between AAR and leptin [44]. A preferential rela-
tionship of AAR with increased subcutaneous adipose tissue, rather than with VAT, might 
partially explain why no association was found with hypoadiponectinaemia [43].
In adolescents, the increased abdominal obesity and reduced adiponectin levels are accompa-
nied by enhanced TG and decreased levels of high‐density lipoprotein cholesterol (HDLc) [1], 
suggesting that central body fat distribution is also associated with a worse control on lipid 
metabolism.
The inverse relation of adiponectin with cardiometabolic risk appears to be accepted, espe-
cially in pubertal subjects. It is important to highlight that the diagnosis of metabolic syn-
drome (MS) in young children (under 10 years) should be avoided, as recommended by the 
International Diabetes Federation, considering the lack of age‐ and gender‐adjusted cut‐offs 
for MS components and the ambiguous causality evidence in such young ages relating MS 
and increased risk of CVD later in life [45].
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4. Adiponectin and cardiometabolic risk factors
4.1. Lipid profile
The effect of adiponectin on lipid metabolism has been widely studied. Adiponectin is known 
to lower the synthesis of free fatty acids and to stimulate β‐oxidation [46]. Furthermore, HMW 
adiponectin seems to lower the release of apolipoprotein (apo) B and apo E from the liver, 
decreasing the release of lipoproteins rich in TG (e.g. very‐low‐density lipoprotein (VLDL)) 
and increasing HDLc levels [47].
The positive association between adiponectin and an improved lipid profile has been con-
firmed by several data. The most consensual effects for adiponectin are a positive association 
with HDLc and a negative correlation with TG [1, 13, 27, 29, 48, 49]. These associations are 
present even in PP ages [26, 50] (Table 1). Through its effect on lipid metabolism, adiponec-
tin might even modulate the influence of genetics. Lower levels of apo B/apo A1 ratios and 
total cholesterol/HDLc were found for individuals with higher adiponectin levels despite pre-
senting an apo E genotype associated with a worse lipid profile [51]. In adolescent OB girls, 
adiponectin levels were positively associated with HDLc measured 7 years later, highlight-
ing that adiponectin might modulate lipid metabolism even for a long term. However, no 
correlation was found between adiponectin and TG or low‐density lipoprotein cholesterol 
(LDLc) [38]. Oppositely, no relation between lipid profile and adiponectin was reported in 
other  paediatric studies [14, 21].
Reference Country n (f %) Age (years) Cohort Adiposity IR Dyslip
Martos‐Moreno et al. [9] Spain 70 (31.4) 8.92 ± 1.80 OB (61 lean CT) NS (‐)
Bansal et al. [50] UK 138 (35.5) 
European; 
77 South 
Asian (35.1)
3 Global population (‐) (‐)#
Gajewska et al. [7] Poland 30 (40.0) 7.8 ± 1.3 OB (35 lean CT) NS
Gil‐Campos et al. [26] Spain 34 (32.4) 9.4 ± 0.4 OB (20 lean CT) (‐)* (‐) (‐)
Medina‐Bravo et al. [33] Mexico 33 (45.4) 9.0 ± 1.6 OB (13 lean CT) (‐)
Murdolo et al. [11] Italy 305 (52.8) 5–13 Global population NS
Gajewska et al. [71] Poland 100 (54.0) 8.3 (7.0–9.3) OB (70 lean CT) (‐)
Nascimento et al. [72] Portugal 13 (46.2) 7.9 ± 1.4 OB (10 lean CT) NS
Murdolo et al. [28] Italy 200 (55.5) 5–13 Global population (‐) NS (‐)#
*, Correlation with total and central adiposity; #, positive correlation with HDL. CT, control; Dyslip, Dyslipidaemia; f, 
female; IR, insulin resistance; (‐), negative association; NS, not significant; OB, obese; OW, overweight.
Table 1. Studies assessing the relation between total adiponectin levels and cardiometabolic risk factors in pre‐pubertal 
children.
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Concerning adiponectin multimers, while LMW adiponectin seems to be linked with a worse 
lipid profile, through a positive association with TG [5], HMW adiponectin has shown oppo-
site effects [6], even in PP individuals [11].
4.2. Blood vessels and blood pressure (BP)
Adiponectin‐positive effects on blood vessels are, apparently, independent of its effect on 
IR [52]. Adiponectin improves vessel status and reduces atherogenesis by inducing nitrous 
oxide production by endothelial cells that promotes vasodilatation and reduces platelet 
adhesion/aggregation. It also reduces vascular smooth muscle cells proliferation [53, 54] and 
avoids macrophage activation, preventing, therefore, vascular wall remodelling and foam 
cells formation [55]. Through these effects, adiponectin prevents the development of athero-
sclerosis while still in early stages. Adiponectin association with vascular changes appears 
since paediatric ages, as its levels are positively correlated with brachial artery distensibility 
[52], and inversely correlated with the internal media thickness (IMT) of carotid arteries (cIMT) 
[56–59]. However, some intervention programmes did not find any correlation between adi-
ponectin improvement and cIMT [13], cIMT variation [60], or retinal vessel diameter [61].
Adiponectin presents anti‐oxidant activity reducing the production of reactive oxygen spe-
cies (ROS) that are deleterious to endothelial cells. Actually, the enhanced production of 
ROS favours the development of oxidative stress, which is a predictive factor for cardio-
vascular events (e.g. coronary artery disease) [62, 63]. In OB children, increased markers 
of oxidative stress have been found together with lower adiponectin levels [64]. The lower 
anti‐oxidant status [65] leads to increased HDL and LDL oxidation in OB children [66]. 
Increased oxidised LDL (oxLDL) is linked to the formation of foam cells, a key step in ath-
erosclerosis initiation. The anti‐oxidant enzyme paraoxonase (PON)1 presents a reduced 
activity in OB subjects, being adiponectin positively correlated with PON1 arylesterase 
activity in OB children [66].
Decreased adiponectin levels are negatively associated with other oxidative stress markers, 
as adipocyte fatty acid‐binding protein (A‐FABP) and lipocalin‐2 [21, 67]. In a 3‐year longitu-
dinal study, higher concentrations of A‐FABP and lower levels of adiponectin were reported 
as predictors for the development of CVD risk factors [21]. The improvement of adiponectin 
levels after an exercise‐based intervention programme has been associated with improve-
ments in the oxidant status in paediatric populations [68].
Similar to their opposite biological effects in lipid metabolism, LMW and HMW adiponectin 
multimers present contrasting activity regarding oxidative stress and vascular changes. An 
increase in systolic BP (SBP), cIMT and oxidative stress (higher‐circulating oxLDL) was posi-
tively associated with LMW% adiponectin [6], while HMW adiponectin correlated inversely 
with a marker of oxidative stress that is increased in OB children—isoprostane [69].
Conflicting results exist in literature regarding the association of adiponectin with BP. Some 
data reported a negative association between adiponectin and both SBP and diastolic BP 
(DBP) [13, 16, 36], or with SBP alone [25, 29, 34, 37, 70]. Fewer studies describe the absence of 
association between adiponectin and BP [14, 27, 49].
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Longitudinal studies usually show no association between fluctuations of adiponectin and 
changes in BP. Choi et al. found in 9‐year‐old children a positive correlation between base-
line adiponectin and BP changes, during a 3‐year follow‐up study; however, the significances 
were lost when adjusted for Tanner stage [21]. Another study [38] reported no association 
between adiponectin concentration in OB 16‐year‐old girls and the values of BP 7 years later.
4.3. Insulin resistance
IR plays a central role in the pathophysiology of obesity‐related co‐morbidities such as dys-
lipidaemia, nonalcoholic fatty liver disease (NAFLD), hypertension and inflammation.
Apart from PP individuals (Table 1), the relation between adiponectin, obesity and IR appears 
to be clear. Total adiponectin levels are negatively correlated with IR, and the increase in adi-
ponectin, following a lifestyle intervention, leadvvvs to a decrease in IR [29, 73]. However, 
there is still some controversy concerning this association [10].
Hepatic IR is particularly important for the metabolic changes observed in obesity, as 
it modifies the profile of lipoproteins released by the liver, towards a more atherogenic 
 profile [47, 74]. IR also leads to TG accumulation in hepatocytes, leading to the develop-
ment of NAFLD. The structural and metabolic changes in hepatocytes induce macrophage 
activation, increasing the hepatic production of inflammatory mediators and transami-
nases [74]. Adiponectin is reduced in OB children and adolescents with NAFLD [75–77], 
and, when adiponectin increases, IR and NAFLD are also improved [75]. Adipose tissue‐
specific IR also accounts for important metabolic and inflammatory changes in OB indi-
viduals, as insulin‐resistant adipocytes release more free fatty acids and proinflammatory 
adipokines [78].
In OB children [6], including PP subjects [12], total adiponectin, and HMW in particular, has 
a more close relation with IR markers, namely with homeostatic model assessment (HOMA), 
than with BMI or body fat. On the contrary, a positive association between LMW% adiponec-
tin and HOMA has been reported [6].
The negative association of adiponectin with IR might not be present from birth. Insulin 
levels increase until 1 year of age, which is accompanied by a reduction in adiponectin; how-
ever, those changes are not associated with HOMA [79]. The inverse association between 
total and HMW adiponectin with IR seems to appear only after 2–6 years of age [11, 14, 
26, 80, 81].
The insulin‐sensitiser effect of adiponectin is likely to explain, in part, why individuals with 
two clinical conditions associated with hyperadiponectinaemia, such as Prader‐Willi syn-
drome (PWS) (associated with cognitive impairment) [82] and Laron syndrome (associated 
with dwarfism) [83], present decreased markers of IR despite severe obesity when compared 
to BMI‐matched CT. HMW% adiponectin is found to be particularly increased in PWS. These 
two syndromes also have in common a diminished level or activity of the growth hormone 
(GH). Changes in this hormone might partially explain their paradoxical hyperadiponec-
tinaemia, increased insulin sensitivity and lower percentage of visceral fat.
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Adiponectin and leptin are closely related, presenting, however, an inverse association with 
adiposity and IR. A study by Schiper et al. showed that an increased inflammatory profile 
increased leptin and leukocyte activation, and IR, in childhood obesity, while lean children 
presented increased adiponectin, insulin sensitivity and lower leukocyte activation [84]. 
Adiponectin‐to‐leptin ratio appears as a relevant marker of IR, with a strong negative associa-
tion with HOMA and insulin. In fact, it might be a better marker than HOMA to predict IR, 
as was shown in OB adolescent cohorts [18, 85]. A cross‐sectional study in Chinese children 
proposed leptin as the best predictor of IR, once adiponectin predicted IR only in OB and OW 
boys and girls, and had no predictive value for lean individuals [32].
The association of adiponectin with IR, adiposity and other CVD markers might be different 
in paediatric populations, with different/special characteristics. The mechanisms underlying 
IR in subjects with type 1 diabetes (T1D) are different from those leading to T2D [86, 87]. In 
adult cohorts of T1D patients, adiponectin is increased, when compared to the general popu-
lation, and is associated with cardiovascular and all‐cause mortality [87]. The exact mecha-
nisms underlying this paradoxal association are still uncertain.
The relation between adiponectin and other metabolic parameters is influenced by the pop-
ulation background. Some ethnic groups, as South Asians (sub‐continental India), showed 
reduced adiponectin levels in infants, despite the normal values of insulin or lipid profile 
[50]. Lower adiponectin is also present in both adult [88] and adolescent black individu-
als [38, 89]. Even though presenting lower adiponectin levels, increased prevalence of IR in 
black adolescents is less clear [38, 89]. It must be highlighted, once again, that the association 
between adiponectin and other metabolic parameters should always be considered regarding 
the ethnicity.
4.4. Adiponectin and markers of inflammation
In paediatric ages, as in adults, obesity is a low‐grade inflammatory state, usually accom-
panied by a rise in proinflammatory mediators, and by a decrease in anti‐inflammatory 
molecules, especially adiponectin. In accordance, adiponectin, in paediatrics, is negatively 
associated with proinflammatory mediators, such as IL‐1β, IL‐6, IL‐8 and tumour necrosis 
factor (TNF)‐α [12]. Different mediators are known to influence adiponectin levels, includ-
ing other adipokines, hormones (e.g. insulin, insulin‐like growth factor 1 (IGF‐1), GH), 
and different types of molecules, produced within the adipose tissue or in other organs 
and tissues.
Inflammatory status appears to vary according to the degree of obesity, as severely OB chil-
dren and adolescents, when compared with individuals presenting a moderate type of obe-
sity, present reduced adiponectin and increased C‐reactive protein (CRP), leptin, IL‐6 and 
resistin [90]. However, this relation between adiponectin, inflammation and the severity of 
obesity is still controversial [51].
Adiponectin reduces TNF‐α secretion by macrophages [88], and both TNF‐α and IL‐6 reduce 
adiponectin mRNA expression, explaining, at least in part, the relations of these cytokines 
with IR [88, 91]. Actually, TNF‐α is known to inhibit insulin signalling [92]. In agreement, 
Lopez‐Alarcon et al. reported that OB and OW adolescents with IR who participated in a 
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1‐month n3 fatty acids supplementation protocol presented an improvement in the inflam-
matory status (higher‐circulating levels of adiponectin and lower TNF‐α and leptin), and of 
IR [93].
In PP individuals, the association between TNF‐α and adiponectin might be less obvious, as 
the studies in this population failed to find any correlation between those adipokines [16, 26]. 
Another study in OB and OW adolescents, presenting a decrease in TNF‐α, IL‐10 and IL‐8 
after weight and body fat loss, following a physical exercise (PE) programme, did not present 
changes in adiponectin [94].
Leptin is one of the adipokines more closely associated to adiposity, presenting a negative 
correlation with adiponectin and a positive correlation with BMI. A 3‐year longitudinal study 
showed that children with the highest increase in BMI presented lower adiponectin and 
increased leptin [3]. Likewise, adiponectin levels were negatively associated with leptin in 
female adolescents [17]. In OB Romanian children, a worse adipokine profile was observed, 
when compared to lean CT, with increased IL‐6, leptin and resistin, and decreased adiponec-
tin, which correlated, negatively, with leptin; this correlation with leptin disappeared when 
corrected for waist circumference (WC) and BMI z‐score. Actually, WC has been proposed as 
a good predictor of adiponectin levels, highlighting the influence of adiposity distribution in 
adipokines [16].
As referred, adiponectin‐to‐leptin ratio might be a better marker of IR than adiponectin and 
leptin separated, or even HOMA [18, 85]. Due to the opposite association of adiponectin and 
leptin with adiposity, this ratio could be also used as an indicator of the anti‐ or proinflamma-
tory adipokine balance in obesity [95].
The adiponectin multimers are also associated with leptin; the HMW adiponectin is nega-
tively correlated, while LMW and LMW% adiponectin present positive associations [5, 6]. 
By contrast, other authors did not find any correlation between adiponectin and leptin [10, 
14, 96] in OW and OB children, despite the association of both adipokines with IR and 
adiposity.
CRP is a well‐recognised marker of CVD risk in adults. Although it has been associated with 
the increased inflammation in paediatric obesity patients [48], its association with adiponectin 
is not so clear in these ages [5, 6, 10, 13, 14, 37, 48, 51]. Nevertheless, there are strong evidence 
that both are related to obesity and IR [48, 51].
IL‐6 is a proinflammatory mediator, usually increased in obesity. In lean individuals, 
IL‐6 controls energy intake but, in OB individuals, a state of resistance to IL‐6 appears to 
develop.
In animal models, resistin was found to associate positively with IR. In human studies, espe-
cially in children, the results are not conclusive. No associations between resistin and total 
adiponectin in children [6, 10, 16, 29], or in PP OB patients [11], as well as with HMW and 
LMW adiponectin [6], were found.
The anti‐inflammatory effect of adiponectin is partially related with IL‐10, an anti‐ 
inflammatory and anti‐atherogenic interleukin, once adiponectin induces the synthesis of 
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IL‐10 by macrophages. Considering that in obesity adiponectin is reduced and an increased 
infiltration of macrophages occurs in the adipose tissue, hypoadiponectinaemia would lead 
to diminished IL‐10 levels. Despite that, increased circulating IL‐10 was reported in OB 
adults. This increase is probably linked to a state of IL‐10 resistance in OB individuals, as 
observed for IL‐6, leptin and insulin. It could be also a response to the obese‐related increase 
in inflammation, as IL‐10 is an anti‐inflammatory mediator [24, 97]. Conversely, Calcaterra 
et al. did not find in OB children, the correlation between adiponectin and IL‐10 reported in 
adults [24].
4.5. Interventional studies and adiponectin levels
Longitudinal studies are crucial to obtain causal associations between adiponectin and other 
factors. Table 2 presents a summary of interventional studies involving PE and/or nutritional 
counselling/supplementation programmes and their impact on adiponectinaemia.
Improvements in adiponectin levels may be obtained by energy restriction and PE, and the 
combination of both approaches appears to have a greater impact, as was observed in OB 
adolescent boys [18]. According to this study, the magnitude of the weight loss does not seem 
to be a confounding factor, as the group practicing only exercise had no significant weight 
loss, but, even so, the adiponectin levels increased. These data raise the hypothesis that varia-
tions in adiponectin levels are closely associated with changes in body composition [18]. 
In fact, even when the weight loss is not significant, changes in plasmatic adiponectin are 
negatively correlated with the variations in body fat percentage, in children [73]. Similarly, 
another interventional study for OB adolescents found that increases in adiponectin levels 
were associated with weight loss, and improvements were kept if the adiposity reduction 
was sustained [98].
Other factors, such as genetics, PE, inflammation and nutritional habits could influence adi-
ponectin levels. For instance, when considering an intervention programme, involving diet 
and PE, performed on OB females with eating disorders (nervous bulimia or binge eating) 
and on BMI‐matched controls, both groups benefited from the intervention, as both presented 
improvements in adiponectin. Nevertheless, changes in adiponectin correlated negatively 
with changes in HOMA and body fat percentage, only in the CT, and baseline and post‐
intervention adiponectin levels did not differ between them [99]. The independent role of 
PE, besides anthropometric improvements, in raising adiponectin levels has also been high-
lighted [100].
Despite the recognised influence of other factors, studies in children and adolescents have 
proposed that significant changes in adiponectin require a marked improvement in adiposity 
[25, 29]. A cut‐off value of BMI z‐score of 0.5 has been proposed as a target for achieving such 
changes [12, 101, 102].
The need for a considerable adiposity reduction in paediatric ages, even when compared to 
adults, in order to obtain significant results regarding adiponectin, is partially linked to the 
age‐related decrease in this adipokine levels that occur during this period of life; this decrease 
is more enhanced during puberty and in boys. In fact, a BMI z‐score reduction of 0.3 in OB 
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Intervention 
programme
Reference Country n (f %) Age (years) Cohort Duration Adiposity IR Effect
EP Shultz et al. [114] New Zealand 14 (57.1%) 16.1 ± 1.6 OB 16 months (+) Programme
Lopes et al. [115] Brazil 17 (100%) 14.6 ± 1.15 OW (17 OW CT) 12 weeks NS Programme
ENCP Lazzer et al. [98] France 26 (53.8%) 12–16 Severely OB 9 months (‐) (+) Programme
Reinehr et al. [116] Germany 37 (64.9%) 8–12 OB 12 months (+) Programme (D‐BMIzsc > 0.5)
Elloumi et al. [18] Tunisia 21 (0%) OB 2 months¥ (+) Programme (> combined 
energy restriction + exercise)
Lee et al. [30] Korea 50 (50.0%) 12.0 ± 0.9 OW + OB 7 days (+) Programme
Roth et al. [12] Germany 62 (54.8%) 11 ± 0.5 OB 12 months (‐) (‐) (+) Programme (D‐BMIzsc>0.5)
Romeo et al. [94] Spain 25 (48.0%) 13–16 OW + OB 13 months NS NS Programme
Reinehr et al. [31] Germany 80 (52.5%) 10.9 ± 0.3 OB 12 months (‐) (+) Programme
Carnier et al. [99] Brazil 83 (66.3%) 15–19 OB* 12 months (‐) (‐) (+) Programme
Leao da Silva et al. [95] 
[22, 41, 59, 60, 75, 117]*
Brazil 84 (59.5%) 15–19 OB 12 months (‐) (+) Programme
Siegrist et al. [96] Germany 402 (59.2%) 13.9 ± 2.3 OW + OB 4–6 weeks (+) Programme
Nemet et al. [100] Israel 21 (47.6%) 10.41 ± 1.96 OB (20 OB CT) 3 months (‐) (+) Programme
Racil et al. [118] Tunisia 34 (100%) 15.9 ± 0.3 OB 12 weeks (‐) (+) Programme
Bluher et al. [10] Germany 65 (46.1%) 12.6 
(11.6–13.9)
OW + OB 12 months NS NS Programme
Bocca et al. [104] Netherlands 75 (72.0%) 4.6 ± 0.8 PP OW + OB 16 weeks NS NS NS Programme
Inoue et al. [119][106, 
120, 121]*
Brazil 45 (62.2%) 16.28 ± 1.34 OB 12 months 
(AT or AET)
(‐) (‐) (+) Programme (AET)NS (AT)
Nascimento et al. [15] Portugal 80 (46.3%) 10.0 ± 2.7 OW + OB (37 OW  
+ OB CT)
8 months (‐) (‐) (+) Programme
Seabra et al. [107] Portugal 58 (0%) 8–12 OB (30 OB CT) 6 months NS Programme
Nunes et al. [68] Brazil 17 (52.9%) 16.18 ± 1.51 OB (8 OB CT) 6 months (+) Programmea
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Intervention 
programme
Reference Country n (f %) Age (years) Cohort Duration Adiposity IR Effect
MENCP Cambuli et al. [73] Italy 48 (45.8%) 10.7 ± 3.2 OW + OB 12 months (‐) (D‐%fat 
mass)NS 
(D‐weight)
(+) Programme
Martos‐Moreno  
et al. [9]
Spain 70 (31.4%) 8.92 ± 1.80 OB 18 months (‐) (T,  
HMW)
(+) Programme
Gajewska et al. [7] Poland 30 (40.0%) 7.8 ± 1.3 PP OB 3 months (+) Programme (T, HMW, HMW% 
and MMW) 
(‐) Programme (LMW%)
Vos et al. [25] Netherlands 40 (55.0%) 13.3 ± 2.0 OB (39 OB CT) 3, 12 and 24 
months
NS Programme
Nascimento et al. [48] Portugal 60 (48.3%) 11.0 ± 2.4 OB 12 months (‐) NS Programme
Gajewska et al. [71] Poland 100 (54.0%) 8.3 (7.0–9.3) PP OB 3 months NS (+) Programme
Huang et al. [29] Mexico 54 (40.7%) 13. 6 ± 1.3 OB 6 months (‐) (WC) NS 
(BMI and 
BMI z‐sc)
NS (+) Programme
Rambhojan et al. [111] Guadalupe 
Island,  
France
55 11–15 OW + OB (28 lean 
CT)
12 months NS (+) Programme
NCP Pedrosa et al. [14] Portugal 61 (55.7%) 7–9 OW + OB 12 months NS NS
Saneei et al. [105] Iran 49 (100%) 11–18 MS 6 weeks (‐) NS (+) Programme
Jensen et al. [122] Australia 74 (74.3%) 13.3 ± 2.0 OB 12 weeks (‐) NS (+) Programme
Rouhani et al. [123] Iran 25 (100%) 12–18 OW + OB (25 OW  
+ OB CT)
10 weeks NS Programme
NSupp Janczyk et al. [124] Poland 76 (14.5%) 13 (11.5‐ 
15.2)
NAFLD OW + OB 6 months (Ω3 
fatty‐acids)
(+) Programme
Machado et al. [125] Brazil 75 (56.0%) 13.7 ± 2.1 OW 11 weeks 
(flaxseed)
NS Programme
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Intervention 
programme
Reference Country n (f %) Age (years) Cohort Duration Adiposity IR Effect
PI Clarson et al. [126] Canada 11 (63.6%) 10–16 IR OB (14 OB CT) 6 months φ (+) Programme
Kendall et al. [127] UK 74 (66.2%) 13.68 ± 2.3 IR OB (77 OB CT) 6 months φ (+) Programme
*, Different studies from the same group with similar results; +, increase of adiponectin with intervention programme; ‐, negative association; ¥, exercise and energy 
restriction, separately or combined; #, 28 with binge eating or bulimia nervous; a, no increase in intervention group versus reduction control group; φ, 1.5 g of metformin 
daily.
 AET, aerobic and endurance training; AT, aerobic training; BMI, body mass index; CT, control; ENCP, Exercise and Nutritional Counselling Programme; EP, Exercise 
Programme; f, female; HMW, high‐molecular weight adiponectin; IR, insulin resistance; LMW, low‐molecular weight adiponectin; MENCP, Motivation to Exercise and 
Nutritional Counselling Programme; MS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; NCP, Nutritional Counselling Programme; NS, not significant; 
NSupp, nutritional supplementation; PI, pharmacological intervention; PP, pre‐puberty; T, total adiponectin; WC, waist circumference.
Table 2. Interventional studies evaluating the effect on adiponectin levels in overweight (OW) and obese (OB) children and adolescents and the relation between changes 
in adiponectin and the variation of adiposity and insulin resistance (IR).
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children, although already associated with improvements in HOMA and lipid profile, only 
prevents the age/puberty‐associated reduction in adiponectin, observed in the group that did 
not reach that cut‐off [48].
Different strategies have been used in interventional studies; those that appear to achieve 
changes in body composition, necessary to obtain improvements in adiponectin, are usually 
short‐term/high‐intensity programmes that are able to produce in a smaller period of time a 
greater adiposity reduction [48]. In agreement, adiponectin increased, while BMI reduced, 
in high‐intensity short‐term intervention protocols lasting 7 days [30] and 4–6 weeks, in OB 
children [96].
Strengthening the importance of weight‐loss magnitude, Lira et al. found that only the OB 
adolescents that reduced more than 5% of their fat mass, following PE and dietary interven-
tion, had an increase in adiponectin levels [22]. Nevertheless, the participants in this study 
were all post‐pubertal (Tanner stage 5) and, thus, the improvement in adiponectin might have 
been facilitated by the absence of the counteracting physiologic reduction. Following a similar 
intervention, by the same group, decreased IR and increased adiponectin levels were associ-
ated with improvements in NAFLD in an OB paediatric population [75].
Regarding the influence of lifestyle interventions on multimeric distribution of adiponectin, 
a study in PP children found that total and HMW adiponectin were lower in OB children 
when compared to lean CT. Variation in multimers, in OB children, is probably associated 
with changes in the multimerisation process that occurs inside the adipocyte, before secretion. 
In OB individuals, there is a reduction in the percentage of MMW and HMW adiponectin, 
while LMW% adiponectin increases [7]. Following a lifestyle intervention in OB PP children, 
a decrease in BMI of 10% was associated with an increase in total adiponectin, along with 
a decrease in LMW% adiponectin and an increase in the percentage of the other multimers 
(HMW% and MMW%), despite no association was observed at baseline, between BMI and the 
multimers or total adiponectin [7]. In a similar way to total adiponectin, changes in multim-
ers concentrations might only be evident if there is a change in body composition, namely a 
reduction in adiposity, as studies that did not achieve significant reductions also did not have 
impact on adiponectin multimer levels [103].
Concerning interventional programmes, not only in adolescents but also (and particularly) in 
children, controversial results are found (Table 2). Indeed, some authors report no association 
with anthropometric changes in PP individuals, as well as no correlation with changes in lipid 
profile and in IR [104].
Adiponectin did not improve after a lifestyle intervention only with nutritional counsel-
ling (without PE programme), despite BMI z‐score reduction and lipid profile improve-
ment being achieved [14]. Likewise, in another study involving PE and diet, even though 
improvements in body fat and BMI were obtained, adiponectin did not increase [94]. 
Changes in adiponectin levels might be harder to obtain even when compared to other 
inflammation markers. For example, a decrease in CRP was present following a nutri-
tional intervention programme, despite no significant changes in adiponectin levels and 
adiposity [105].
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The type of PE chosen, namely the training routines and intensity used, will influence the 
results obtained regarding the body composition and cardiorespiratory fitness and, conse-
quently, adiponectin levels [94, 106, 107]. For instance, although improvements in visceral fat, 
BMI and dyslipidaemia were obtained by both aerobic training (AT) and aerobic combined 
with endurance training (AET), these changes were greater with AET, which also presented 
a significant increase in adiponectin and reduction of IR. It was hypothesised that the greater 
improvement in dyslipidaemia and IR observed in the AET group was partially caused by the 
increase found for adiponectin in these individuals, but absent in the AT group [106].
Differences in baseline body composition and physical fitness might also influence the 
impact of intervention protocols on inflammation mediators, namely on adiponectin. Studies 
 involving non‐OB subjects or a mixed population can present different results from those 
found when only OB individuals are included. Ballet, for instance, is characterised by intense 
physical activity (PA), associating with an increase in lean mass. Girls practicing ballet have 
increased adiponectinaemia, when compared to lean CT. Moreover, their adiponectin levels 
increased during pubertal years (contrarily to CT), despite the trend towards central fat dis-
tribution following an increase in BMI z‐score in this group [108].
A school‐based study in Denmark did not find changes in adiponectin after a 6‐week‐day 
camp intervention (involving PA and health classes), although reduction in CRP and leptin 
and beneficial changes in body composition were achieved [109]. Contrarily, a 12‐week 
exercise intervention study with lean adolescents males found an increase in adiponectin, 
IL‐6 and CRP, although none of these changes were associated with variations in body fat 
composition [110]. Similar results were found in other studies [111]. It is known that PE, par-
ticular high‐intensity PE, increases oxidative stress and inflammation markers [112]. As the 
metabolic profile, the inflammatory balance also differs between lean and OB individuals, 
with the last presenting a turn towards a more proinflammatory profile. Thus, it is likely 
that their response to interventional studies also vary, suggesting that comparisons should 
be done carefully.
A longitudinal study involving only PP lean individuals reported a negative association 
between adiponectin and the level of PA. Also, the traditional negative association between 
adiponectin and IR was influenced by the PA levels in this cohort, being stronger for the 
less‐active groups. A mechanism of negative feedback might be present, as children with 
increased levels of PA would present greater insulin sensitivity (consequence of the PE), mak-
ing the insulin‐sensitiser agent adiponectin less ‘necessary'. The opposite effect would occur 
in the less‐active individuals [113]. This postulated negative feedback could also occur in OB 
individuals participating in interventional programmes, and cause a reduction in adiponec-
tin, following the initial increase, as the intervention continued, due to the increased insulin 
sensitivity [30]. Actually, in T1D children the increase in IR is accompanied by higher levels 
of circulating adiponectin [128, 129].
Pharmacological strategies to tackle obesity and obesity‐related co‐morbidities have been 
explored. Metformin associates with a small, but consistent, BMI reduction, and increases 
adiponectin and adiponectin‐to‐leptin ratio in OB children and adolescents, without notice-
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able side effects. Still, the effect of long‐term maintenance of metformin on adiponectin levels 
in children and adolescents is still unknown, particularly in children; thus, its use should be 
carefully considered [126, 127].
In conclusion, adiponectin association with obesity‐related cardiometabolic risk factors, 
such as IR, dyslipidaemia, atherosclerosis and NAFLD, have been well demonstrated. 
Interventional studies are good options to tackle obesity and the referred co‐morbidities, 
pharmacological adjuvants being an option to be considered. The variety of interventional 
approaches, with different study designs, populations and PE protocol makes the impact of 
these interventions on inflammatory mediators, and particularly on adiponectin, less clear; 
however, a positive effect is almost consistently found.
5. Conclusions and final remarks
The relation between adiponectin and cardiometabolic risk in children and adolescents is still 
under research.
Considering the different adiponectin multimers, HMW adiponectin has been associated 
with a better metabolic control, improving IR, while the LMW multimer presents an opposite 
effect. The concentrations and the relative percentage of the multimers should be considered 
as potential markers of CVD risk.
Obesity, and particularly abdominal obesity, is closely associated with lower adiponectin values in 
paediatric ages. Adiponectin acts as an insulin sensitiser, decreasing as the IR rises. Nevertheless, 
there might be a negative feedback mechanism, causing a relative decrease in adiponectin as 
insulin sensitivity improves. Higher adiponectin levels are associated with an improvement in 
lipid profile, with decreased TG and increased HDLc, being the influence on LDLc more lim-
ited. Besides the contribution to a less atherogenic lipid profile, adiponectin further prevents 
atherosclerosis by a direct positive effect on blood vessels. It reduces the formation of foam 
cells, macrophage infiltration and activation, and the vascular wall remodelling. Adiponectin is 
also associated with smaller arterial IMT and increased vessel elasticity, in children. Likewise, 
increased adiponectin is linked to reduced, healthier, BP.
Combining the specific effects of adiponectin in lipid profile, BP and IR, a decrease in this 
adipokine will induce clustering of several cardiovascular risk factors in OB children and 
adolescents that predicts cardiometabolic diseases in the future.
HMW adiponectin seems to be a better predictor of cardiometabolic risk factors than total 
adiponectin. An increase in total and HMW adiponectin is achieved following interventional 
programmes, particularly those involving exercise and diet interventions. Changes in body 
composition, with reduction of total and central body fat, more than changes in body weight, 
appear to be the key for therapeutic success.
The positive effects of adiponectin on general metabolism are not so clear in PP individuals, 
particularly the improvement in IR. No significant differences are usually observed between 
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genders in PP individuals. After puberty, and possibly through a mechanism involving sexual 
hormones, adiponectin decreases with age in both genders, more markedly in boys [72, 130]. 
Several studies have reported similar adiponectin levels for both genders, even in OB paedi-
atric populations involving post‐pubertal subjects [10, 29, 61, 111, 131].
The controversial data on adiponectin following interventional programmes are, probably, 
related to different study designs and strategies used, including age, nutritional/body compo-
sition characterisation and pubertal stage of the studied subjects, PE or PA practice and type 
(e.g. aerobic, endurance, strength), group or individual therapy, among others; the popula-
tion background should also be considered, as genetics plays an important part on adipo-
nectin‐circulating levels and, thus, might affect the results. Different populations also have 
different diets, and nutritional influence on adiponectin levels deserves further studies. Thus, 
although it is hard to control all variables, a good characterisation of the interventional studies 
is crucial for future comparisons.
Adiponectin, obesity and IR are so closely associated that it is hard to establish which are 
causes and which are consequences. The clarification of adiponectin physiological role, 
the evolution of its normal values throughout life and its relation with other metabolic 
markers and diseases need well‐designed and objective longitudinal studies. These stud-
ies should focus on increased follow‐up periods, including PP and CT individuals, and 
evaluate adiponectin isoforms, considering the lack of information on individual multi-
mer levels and function. Further studies would help to better understand the metabolic 
changes in obesity, and to find new therapeutic targets to obesity itself and obesity‐related 
complications.
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